18:49 , Nov 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Arthritis Mouse studies suggest inhibiting MCP-1 or its receptor CCR2 could help treat arthritis. In a mouse model of anti-collagen antibody-induced arthritis, systemic MCP-1 knockout or a neutralizing antibody against CCR2 decreased disease severity...
17:58 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample, cell culture and mouse studies suggest inhibiting STAT3 or immune checkpoint inhibitors could help treat idiopathic pulmonary fibrosis (IPF) or sarcoidosis-associated pulmonary fibrosis. In IPF patients, lung levels of PD-1...
17:46 , Oct 19, 2018 |  BC Week In Review  |  Financial News

Krystal raises $60M following Phase I/II gene therapy readout

On the heels of reporting data for its topical gene therapy, Krystal Biotech Inc. (NASDAQ:KRYS) raised $60 million late Oct. 18 through the sale 3 million shares at $20 in a follow-on underwritten by Cowen,...
17:11 , Oct 19, 2018 |  BC Week In Review  |  Clinical News

Krystal's topical gene therapy meets endpoints in two patients with skin blistering disease

Krystal Biotech Inc. (NASDAQ:KRYS) reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa. KB103...
20:49 , Oct 15, 2018 |  BC Extra  |  Clinical News

Krystal gains on early data for topical gene therapy in skin blistering disease

Krystal Biotech Inc. (NASDAQ:KRYS) added $4.32 (28%) to $20 on Monday when it reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints...
19:25 , Oct 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cardiovascular

INDICATION: Hypertension Patient sample, cell culture, mouse and rat studies suggest inhibiting ENO1 could help treat pulmonary arterial hypertension (PAH) associated with other conditions. In pulmonary artery smooth muscle cell samples from patients with PAH...
16:44 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Histogenics' NeoCart misses in Phase III for knee cartilage repair

Histogenics Corp. (NASDAQ:HSGX) said NeoCart missed the primary endpoint of improving pain and function at one year in a Phase III trial to repair knee cartilage damage. The company said the product narrowly missed the...
16:45 , Sep 7, 2018 |  BC Week In Review  |  Clinical News

Bridge's BBT-877 reduces lung fibrosis in mouse model of IPF

Bridge Biotherapeutics Inc. (Seongnam, South Korea) said BBT-877 reduced lung fibrosis as measured by Ashcroft scores and deposition of collagen in a mouse model of bleomycin-induced idiopathic pulmonary fibrosis (IPF). Data were presented at the...
21:49 , Aug 29, 2018 |  BC Extra  |  Preclinical News

Sequential therapies trigger axon regeneration in spinal cord injury

University of California Los Angeles and Swiss Federal Institute of Technology Lausanne (EPFL) researchers showed delivery of three sequential therapies could trigger axon growth after complete spinal cord injury in rodents, suggesting the combination approach...
20:10 , Aug 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Pulmonary

INDICATION: Pulmonary fibrosis Patient sample and mouse studies suggest GLRX could help treat idiopathic pulmonary fibrosis (IPF). In lung tissue samples from IPF patients, GLRX levels were lower than in lung samples from healthy volunteers....